Quarterly report · Q1
9776.TEDINET S100RLX2
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.9bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥76m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥132m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥81m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥223m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥74m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥222m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥78m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥125m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥1.72 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.35 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.2% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥18m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥18m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥855,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥12m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥62m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥108m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥431m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥265m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥166m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥4m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.9bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥166m |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥166m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥178m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥846,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥15m |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥200m |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥78m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥376m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥233m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥3m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥143m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥275m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥144m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥290m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 376
| Item | Context | Value | Unit |
|---|---|---|---|
| Cost of lease revenue noe | Prior1YTDDuration | 11689000 | JPY |
| Cost of lease revenue noe | CurrentYTDDuration | 9903000 | JPY |
| Other noe | Prior1YTDDuration | 10000 | JPY |
| Other noe | CurrentYTDDuration | 193000 | JPY |
| Non operating expenses | Prior1YTDDuration | 13730000 | JPY |
| Non operating expenses | CurrentYTDDuration | 11918000 | JPY |
| Ordinary income | Prior1YTDDuration | 223408000 | JPY |
| Ordinary income | CurrentYTDDuration | 80888000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 14000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | － | JPY |
| Extraordinary income | Prior1YTDDuration | 14000 | JPY |
| Extraordinary income | CurrentYTDDuration | － | JPY |
| Loss on sales of noncurrent assets el | Prior1YTDDuration | － | JPY |
| Loss on sales of noncurrent assets el | CurrentYTDDuration | 6707000 | JPY |
| Loss on retirement of noncurrent assets el | Prior1YTDDuration | 1188000 | JPY |
| Loss on retirement of noncurrent assets el | CurrentYTDDuration | 114000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 1188000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 6821000 | JPY |
| Income before income taxes | Prior1YTDDuration | 222234000 | JPY |
| Income before income taxes | CurrentYTDDuration | 74067000 | JPY |
| Income taxes | Prior1YTDDuration | 96994000 | JPY |
| Income taxes | CurrentYTDDuration | 64870000 | JPY |
| Profit loss | Prior1YTDDuration | 125239000 | JPY |
| Profit loss | CurrentYTDDuration | 9196000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 47120000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 3484000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 78119000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 5711000 | JPY |
| Profit loss | Prior1YTDDuration | 125239000 | JPY |
| Profit loss | CurrentYTDDuration | 9196000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -4772000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 6509000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -4772000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 6509000 | JPY |
| Comprehensive income | Prior1YTDDuration | 120467000 | JPY |
| Comprehensive income | CurrentYTDDuration | 15706000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 73346000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 12221000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 47120000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 3484000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 2096762000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 2548224000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember | 232671000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 4877657000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 22392000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4900050000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember | 142990000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 142990000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |